Halozyme Therapeutics, Inc.
HALO· Nasdaq
HALOHalozyme Therapeutics, Inc.
Filed Feb 21, 2023 · 10-K · 52 days after period end · 0001159036-23-000012
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $181.50M | $102.00M | $121.70M | $53.67M |
| Net Income | $57.70M | $66.77M | $73.16M | -$34.40M |
| EPS Diluted | — | — | $0.50 | -$0.24 |
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Feb 21, 2023 · 52 d after period end
